S F Slovin

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer
    Michael J Morris
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:679-83. 2002
  2. ncbi request reprint Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy
    Susan F Slovin
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:8669-73. 2005
  3. ncbi request reprint Violaceous exanthem as a manifestation of metastatic prostate cancer in skin
    Susan F Slovin
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 67:420. 2006
  4. doi request reprint A clinical trials outcome paradox: should survival prevail in the absence of clinical benefit?
    Susan F Slovin
    Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Immunotherapy 2:155-8. 2010
  5. doi request reprint Biomarkers for immunotherapy in genitourinary malignancies
    Susan F Slovin
    Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY Electronic address
    Urol Oncol 34:205-13. 2016
  6. doi request reprint Metabolism and pharmacokinetics of radium-223 in prostate cancer
    Oladapo Yeku
    Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, Genitourinary Oncology Service, 1275 York Avenue, New York, NY 10065, USA 1 646 422 4470
    Expert Opin Drug Metab Toxicol 11:843-9. 2015
  7. pmc Toward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapy
    Susan R Slovin
    Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center New York, NY, USA
    Front Oncol 2:43. 2012
  8. pmc Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
    S F Slovin
    Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Ann Oncol 24:1813-21. 2013
  9. doi request reprint Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs
    Susan F Slovin
    Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Immunotherapy 5:1347-55. 2013
  10. doi request reprint A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer
    Susan F Slovin
    Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Vaccine 31:943-9. 2013

Detail Information

Publications59

  1. ncbi request reprint Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer
    Michael J Morris
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:679-83. 2002
    ..To evaluate the safety and pharmacokinetics of BCL-2 antisense oligonucleotide (G3139) administered by prolonged i.v. infusion in patients with advanced cancer...
  2. ncbi request reprint Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy
    Susan F Slovin
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:8669-73. 2005
    ....
  3. ncbi request reprint Violaceous exanthem as a manifestation of metastatic prostate cancer in skin
    Susan F Slovin
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 67:420. 2006
  4. doi request reprint A clinical trials outcome paradox: should survival prevail in the absence of clinical benefit?
    Susan F Slovin
    Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Immunotherapy 2:155-8. 2010
    ..This study brings to light improved survival for patients, but the issue of how to reconcile a survival advantage in the absence of significant clinical anti-tumor response remains unsettled...
  5. doi request reprint Biomarkers for immunotherapy in genitourinary malignancies
    Susan F Slovin
    Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY Electronic address
    Urol Oncol 34:205-13. 2016
    ..How to design immunologic end points that reflect a meaningful effect on the cancer remains a challenge for clinical trial development. The issues faced by clinical investigators and the current state of immune monitoring are discussed. ..
  6. doi request reprint Metabolism and pharmacokinetics of radium-223 in prostate cancer
    Oladapo Yeku
    Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, Genitourinary Oncology Service, 1275 York Avenue, New York, NY 10065, USA 1 646 422 4470
    Expert Opin Drug Metab Toxicol 11:843-9. 2015
    ..As such, there has been intense interest in the development of strategies and pharmaceuticals to address this problem...
  7. pmc Toward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapy
    Susan R Slovin
    Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center New York, NY, USA
    Front Oncol 2:43. 2012
    ..The ideal treatment approach remains unclear; advances in biomarker validation and trial design may likely improve our ability to assess biologic benefit irrespective of the development of true antitumor immunity...
  8. pmc Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
    S F Slovin
    Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Ann Oncol 24:1813-21. 2013
    ....
  9. doi request reprint Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs
    Susan F Slovin
    Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Immunotherapy 5:1347-55. 2013
    ..The continued evolution of novel antibody-drug and antibody-imaging constructs will probably offer more efficient ways to deliver a therapeutic to the tumor and enhance imaging of active or treated sites of disease. ..
  10. doi request reprint A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer
    Susan F Slovin
    Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Vaccine 31:943-9. 2013
    ..PSMA-VRP was well-tolerated at both doses. While there did not appear to be clinical benefit nor robust immune signals at the two doses studied, neutralizing antibodies were produced by both cohorts suggesting that dosing was suboptimal...
  11. ncbi request reprint Chemotherapy and immunotherapy combination in advanced prostate cancer
    Susan Slovin
    Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Adv Hematol Oncol 10:90-100. 2012
    ..Patient characteristics, prostate cancer disease stage, and treatment history also may influence the response to combined therapy. Advances in biomarker validation and trial design are needed to efficiently investigate these issues...
  12. ncbi request reprint Prostate-specific membrane antigen vaccines: naked DNA and protein approaches
    Susan F Slovin
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center New York, NY 10021, USA
    Clin Prostate Cancer 4:118-23. 2005
    ..This review serves to present unique approaches in vaccine development that can induce immunologic responsiveness to PSMA with potential impact on disease progression...
  13. doi request reprint Tribulations or triumphs in prostate cancer immunotherapy: on the road to victory?
    Susan F Slovin
    Sidney Kimmel Center for Prostate and Urologic Cancers, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10065, USA
    Expert Rev Anticancer Ther 8:465-74. 2008
    ..However, no one approach has been able to show improved overall survival. This article reviews the current issues and potential resolutions as to how we might go forward in developing and interpreting immunologic trials...
  14. ncbi request reprint Neuroendocrine differentiation in prostate cancer: a sheep in wolf's clothing?
    Susan F Slovin
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Urol 3:138-44. 2006
    ..This review outlines the difficulties in treating this disease, both at the time of diagnosis and in the metastatic setting, and focuses on an area of research that remains challenging to both the researcher and clinician...
  15. pmc Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man
    S F Slovin
    Division of Genitourinary Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 96:5710-5. 1999
    ....
  16. ncbi request reprint Immunologic targeting: how to channel a minimal response for maximal outcome
    Susan F Slovin
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Curr Opin Urol 16:179-85. 2006
    ....
  17. doi request reprint Pitfalls or promise in prostate cancer immunotherapy-which is winning?
    Susan F Slovin
    Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancer, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer J 14:26-34. 2008
    ..This article is a review of the current issues and potential resolutions as to how we might go forward in developing and interpreting immunologic trials...
  18. ncbi request reprint Emerging role of immunotherapy in the management of prostate cancer
    Susan F Slovin
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 21:326-33; discussion 334, 338, 346-8. 2007
    ..This review explores the challenges now faced in establishing a role for immune therapies for prostate cancer treatment...
  19. ncbi request reprint A polyvalent vaccine for high-risk prostate patients: "are more antigens better?"
    Susan F Slovin
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Immunol Immunother 56:1921-30. 2007
    ..No impact on PSA slope was detected. We address the relevance of the multivalent approach for prostate cancer treatment...
  20. ncbi request reprint Fifth International Prostate Cancer Congress. 1-3 July 2005, Rio Grande, Puerto Rico
    Susan F Slovin
    Memorial Sloan Kettering Cancer Center, Genitourinary Oncology Service, 1275 York Avenue, New York, NY 10021, USA
    IDrugs 8:710-2. 2005
  21. ncbi request reprint Carbohydrate vaccines as immunotherapy for cancer
    Susan F Slovin
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Immunol Cell Biol 83:418-28. 2005
    ..The approaches for synthesis, conjugation, clinical administration and immunological potential are discussed...
  22. ncbi request reprint Vaccines as treatment strategies for relapsed prostate cancer: approaches for induction of immunity
    S F Slovin
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Hematol Oncol Clin North Am 15:477-96. 2001
    ..The varying approaches toward vaccine construction as treatment strategies for relapsed prostate cancer are described...
  23. ncbi request reprint Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior
    Susan F Slovin
    Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Oncol 4:551-4. 2007
    ..One should be alerted to this phenotype in a patient with large volume disease on biopsy or examination and a low PSA or PSA not in proportion to tumor burden...
  24. ncbi request reprint Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine
    Susan F Slovin
    Genitourinary Solid Tumor Service, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:4292-8. 2003
    ....
  25. ncbi request reprint Cancer immunotherapeutics meeting
    Susan F Slovin
    Memorial Sloan Kettering Cancer Center, Genitourinary Oncology Service, 1275 York Avenue, New York, NY 10021, USA
    Expert Opin Investig Drugs 13:1645-50. 2004
    ..Another goal of this meeting was to foster collaborations among investigators to facilitate and extend current research objectives...
  26. doi request reprint Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer
    Susan F Slovin
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Genitourin Cancer 7:E77-82. 2009
    ..The secondary endpoint was to assess the efficacy of cetuximab in combination with doxorubicin as well as to determine the optimal biologic dose and the maximum tolerated dose...
  27. ncbi request reprint Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer
    Susan F Slovin
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immunol Immunother 54:694-702. 2005
    ..The results justify the inclusion of TF(c) at a dose of 1 microg as a relevant antigenic target in a multivalent phase II vaccine trial in patients in the high-risk minimal disease state...
  28. ncbi request reprint A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21
    Susan F Slovin
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Vaccine 23:3114-22. 2005
    ..Compared with a subsequent trial with the same bivalent vaccine plus QS-21 at the maximal tolerated dose of 100 microg, the 5000 microg dose of GPI-0100 produced comparable antibody titers...
  29. pmc Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen
    Susan F Slovin
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Expert Opin Ther Targets 9:561-70. 2005
    ..This review serves to present unique approaches in vaccine development which can induce immunological responsiveness with potential impact on disease progression and to introduce PSMA as a potential target for multimodality therapies...
  30. ncbi request reprint Prostate cancer vaccines: maximizing a suboptimal immune response for improved outcome
    Susan F Slovin
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Adv Hematol Oncol 5:972-80. 2007
    ..This review updates the status of prostate cancer vaccines as tools for induction of active immunity and discusses the issues relevant to their clinical trial development...
  31. ncbi request reprint A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in patients (pts) with castration-resistant prostate cancer (CRPC): Preliminary results
    S F Slovin
    Memorial Sloan Kettering Cancer Center, New York, NY Progenics Pharmaceuticals, Inc, Tarrytown, NY
    J Clin Oncol 29:140. 2011
    ..We report preliminary results of a first in human trial using PSMA VRP to elicit immune responses targeting PSMA...
  32. ncbi request reprint Phase I study of docetaxel (Tax) and 153Sm repetitively administered for castrate metastatic prostate cancer (CMPC)
    M J Morris
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 26:5001. 2008
    ..sup>153Sm-lexidronam (Sm) (Quadramet, Cytogen Corp.) is a radiopharmaceutical with a 46.3 hour T1/2 and a favorable toxicity profile...
  33. doi request reprint Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer
    Matthew D Galsky
    Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 26:2147-54. 2008
    ..This novel immunoconjugate has shown cytotoxic anti-prostate cancer activity. This study investigated the safety profile, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MLN2704...
  34. ncbi request reprint DNA vaccines: an active immunization strategy for prostate cancer
    Jedd D Wolchok
    Clinical Immunology Services, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 30:659-66. 2003
    ..We are currently conducting a phase I trial of human and mouse PSMA DNA vaccines in patients with recurrent prostate cancer, based on preclinical experiments described below...
  35. ncbi request reprint Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration
    O Smaletz
    Department of Medicine, Division of Solid Tumor, Memorial Sloan Kettering Cancer Center, Joan and Sanford I Weill Medical College of Cornell University, New York, NY 10021, USA
    Ann Oncol 14:1518-24. 2003
    ..We conducted a dose-escalation study to determine a safe dose of BMS-247550 to combine with EMP in patients with metastatic prostate cancer...
  36. ncbi request reprint Chemotherapy for androgen- independent prostate cancer: myth or reality
    W K Kelly
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Joan and Sanford Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 2:394-401. 2000
    ..These data suggest that prostate cancer is not as resistant to chemotherapy as it was once thought to be...
  37. ncbi request reprint The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool for collecting the invisible costs of androgen independent prostate carcinoma
    E J Sherman
    Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer 91:841-53. 2001
    ..Considering the potentially significant impact on total costs, DNM/IC data should be included in future cost-analysis studies of patients with AIPC and other diseases...
  38. ncbi request reprint HER-2 profiling and targeting in prostate carcinoma
    Michael J Morris
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 94:980-6. 2002
    ..This study explored the feasibility of molecular profiling to determine the correlation between HER-2 expression, hormonal sensitivity, and the antitumor effects of trastuzumab and paclitaxel in patients with prostate carcinoma...
  39. ncbi request reprint Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC)
    S F Slovin
    Memorial Sloan Kettering Cancer Center, New York, NY Oregon Health and Science University, Portland, OR University of Washington School of Medicine, Seattle, WA Henry Ford Health System, Detroit, MI The Angeles Clinic and Research Institute, Santa Monica, CA Washington University School of Medicine, St Louis, MO UCSF School of Medicine, San Francisco, CA Medarex, Inc, Bloomsbury, NJ
    J Clin Oncol 27:5138. 2009
    ..In the dose escalation part of this Phase I/II trial 10 mg/kg dosing of IPI with or without prior priming by single fraction XRT was feasible. We now report initial phase II results...
  40. ncbi request reprint Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer (mCRPC): Results of a phase I pilot study
    D E Rathkopf
    Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 29:e15081. 2011
    ....
  41. ncbi request reprint Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy
    D C Danila
    Memorial Sloan Kettering Cancer Center, New York, NY Cougar Biotechnology, Los Angeles, CA
    J Clin Oncol 26:5019. 2008
    ..5019 Background: A proportion of CRPC overexpress androgen synthetic enzymes and are dependent on androgens for growth. Abiraterone acetate (AA) inhibits 17 α-hydroxylase and C17,20-lyase to decrease serum androgen to undetectable levels...
  42. pmc A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer
    M J Morris
    Department of Medicine, Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Ann Oncol 23:2714-9. 2012
    ....
  43. ncbi request reprint Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group
    Howard I Scher
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 22:537-56. 2004
    ..To define methodology to show clinical benefit for patients in the state of a rising prostate-specific antigen (PSA)...
  44. ncbi request reprint Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Appl Immunohistochem Mol Morphol 13:6-13. 2005
    ..These data support the dose selection of ongoing phase 2 studies of G3139 at 7 mg/kg/d and docetaxel 75 mg/m2...
  45. pmc Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur Urol 56:237-44. 2009
    ..Growth of selected castration-resistant prostate cancer (CRPC) cell lines and animal models can be repressed by reexposure to androgens. Low doses of androgens, however, can stimulate tumor growth...
  46. pmc Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer
    Dana Rathkopf
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 26:2959-65. 2008
    ..We evaluated rapid androgen cycling in combination with docetaxel for men with progressive noncastrate prostate cancers...
  47. ncbi request reprint Phase I/II study of docetaxel and 153Sm for castrate metastatic prostate cancer (CMPC): Summary of dose-escalation cohorts and first report on the expansion cohort
    M J Morris
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 27:5057. 2009
    ..Here we summarize the dose-escalation cohorts and safety/efficacy data from the expansion cohort of 24 pts...
  48. ncbi request reprint Phase I trial of a PSMA DNA vaccine for patients(pts) with good risk renal cell carcinoma(RCC)
    S F Slovin
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 26:16073. 2008
    ..Good risk pts were defined as having a KPS of >80%, prior nephrectomy, normal calcium and hemoglobin levels...
  49. pmc Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas
    Xingxing Zang
    Howard Hughes Medical Institute, Immunology Program, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 23:1104-12. 2010
    ..B7-H3 expression in tumor vasculature may be a reflection of tumor aggressiveness and has diagnostic and immunotherapeutic implications in ovarian carcinomas...
  50. doi request reprint Scrotal and penile papules and plaques as the initial manifestation of a cutaneous metastasis of adenocarcinoma of the prostate: case report and review of the literature
    Steven Q Wang
    Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Cutan Pathol 35:681-4. 2008
    ..We also review the literature on this subject...
  51. ncbi request reprint A phase I dose-escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in patients (pts) with castration-resistant prostate cancer (CRPC): Final results
    S F Slovin
    Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY Progenics Pharmaceuticals, Inc, Tarrytown, NY Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 29:e15170. 2011
    ..The PSMA gene is encoded by a subgenomic mRNA leading to high level expression of PSMA protein and presentation to the immune system. We report preliminary results of a first in human trial...
  52. ncbi request reprint A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC)
    D E Rathkopf
    Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 29:TPS190. 2011
    ..A phase I/II clinical trial of continuous oral ARN-509 in patients with progressive CRPC with and without prior chemotherapy began in July 2010...
  53. ncbi request reprint Second-line chemotherapy for prostate cancer: patient characteristics and survival
    Kathleen W Beekman
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Prostate Cancer 4:86-90. 2005
    ..The use and outcomes of chemotherapy after first-line antimicrotubule-based therapy have not been well described...
  54. pmc Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
    David B Solit
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:1775-82. 2007
    ..To define the maximum tolerated dose (MTD), toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when administered using continuous and intermittent dosing schedules...
  55. pmc Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research
    Michael J Morris
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Genitourin Cancer 7:51-7. 2009
    ..This is the first report of the Prostate Cancer Clinical Trials Consortium (PCCTC)...
  56. pmc Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage
    R Houston Thompson
    Department of Surgery, Urology Service, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Res 68:6054-8. 2008
    ..These early results merit further investigation of this serum marker for potential diagnostic and prognostic purposes...
  57. ncbi request reprint Dendritic cell vaccines--hopeful or hopeless?
    Susan F Slovin
    Cancer Invest 21:969-70. 2003
  58. ncbi request reprint Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer
    Nancy A Dawson
    Genitourinary Oncology Program, Greenebaum Cancer Institute, University of Maryland, Baltimore, Maryland 21201, USA
    Urology 62:102-18. 2003
    ..Patients enrolling in these trials need to be clearly informed of the limited expectations of these novel exploratory approaches...
  59. ncbi request reprint Chemotherapeutic response with single agent gemcitabine in metastatic Bellini duct tumor
    Susan F Slovin
    Cancer Invest 22:818-21. 2004